Two cases of vena caval thrombosis in infants were successfully treated with low dose (0-01-0-05 mg/kg/hour) local infusions oftissue plasminogen activator after conventional anticoagulant treatment had been unsuccessful. This approach is useful for clots associated with indwelling intravascular catheters, and a low dose infusion of tissue plasminogen activator as a regional application is recommended to achieve clot lysis with minimal systemic effects. (Arch Dis Child 1992;67:1483-4) An infusion ofrecombinant tissue plasminogen activator was started through the Hickman line at a dose of 0-01 mg/kg/hour. This was increased to 0-05 mg/kg/hour after four hours, and after 24 hours of treatment improvement in the swelling and oedema was noted. An ultrasound examination showed blood flow through the innominate veins and superior vena cava.
Six weeks after the operation an ultrasound examination of the inferior vena cava showed a large thrombus extending from the tip of a right femoral vein catheter and occupying most of the inferior vena cava. Warfarin was discontinued and recombinant tissue plasminogen activator given through the femoral vein catheter at an initial dose of 0 01 mg/kg/hour. This was increased to 0-02 mg/kg/hour after six hours and was continued for six days. Serial ultrasound examinations showed complete lysis of the clot over this period. The infant was then treated with an intravenous infusion of heparin followed by warfarin by mouth.
There was no bleeding during the infusion of tissue plasminogen activator. The fibrinogen concentration was always greater than 1 5 g/l and the D-dimer concentration between 0-2 and 4 mg/I. Discussion Tissue plasminogen activator is a naturally occurring protein which plays a part in the fibrinolytic cascade. It catalyses the conversion of the inactive proenzyme plasminogen into the active serine protease plasmin. Tissue plasminogen activator has a high affinity for fibrin and the tissue plasminogen activator-fibrin complex enhances the binding of plasminogen to fibrin. This fibrin bound plasminogen is broken down to produce plasmin locally at the site of the clot. This clot selective mechanism, together with the low affinity of tissue plasminogen activator for circulating plasminogen, is thought to minimise the systemic thrombolytic effects of tissue plasminogen activator.
Bleeding may be reduced by the regional application of tissue plasminogen activator directly onto the clot with the assumption that the thrombolytic effect will be entirely local. This is attractive for clots associated with indwelling intravascular catheters which may be used as the treatment route.
Our two patients received a low dose infusion of tissue plasminogen activator as a regional application to try to achieve clot lysis with minimal systemic effects.
A similar low dose (005 mg/kg/hour) regional infusion of tissue plasminogen activator has been used in four neonates with caval thrombosis secondary to indwelling intravascular catheters.2 There was successful lysis of the clot in three of the patients. In one patient the infusion caused a decrease in fibrinogen concentrations and an increase in fibrin degradation products and this infant had an intraventricular haemorrhage.
When higher doses of tissue plasminogen activator (O -1-0-5 mg/kg/hour) were given to 12 children,3 six had bleeding complications. In these six patients bleeding was associated with a tissue plasminogen activator dose of 046-0 50 mg/kg/hour).
The age of the clot to be lysed has an important effect on its susceptibility to thrombolysis. Most in vivo studies suggest that clots become more resistant to lysis as they age.4 
